| Name | Title | Contact Details |
|---|
Vittamed is an early stage medical technology company developing innovative ultrasound-based non-invasive neuro diagnostic and monitoring technologies including the measurement of absolute value of intracranial pressure, real time cerebral blood flow autoregulation and intracranial volumetric wave monitoring.
Creganna is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ZipLine® Medical is developing and commercializing innovative tissue repair devices to address the clinical need for rapid, non-invasive and easy-to-use skin closure. ZipLine`s PRELOC™ technology platform provides uniform closure forces while minimizing scar-promoting tension along the wound. Utilizing our patented technology, we believe that physicians can achieve the best of both worlds — the speed of staples with the cosmetic outcome of a meticulous suture closure. Our initial strategy focuses on procedures where the non-invasive, speed and cosmetic benefits of our technology have the greatest impact. Since skin closure is a part of most surgical procedures, our technology platform has broad application across various surgical specialties and emergency medicine. ZipLine Medical was founded in 2009 by Amir Belson, M.D. and is located in Silicon Valley, with access to a wealth of expertise in medical device research and development
Kurve Technology is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.